Gene linked to diabetes risk under the microscope in new trial
NCT ID NCT06972407
First seen Nov 01, 2025 · Last updated Jun 22, 2026 · Updated 28 times
Summary
This study will test how a common genetic variation (rs7903146) affects the body's ability to produce insulin and control blood sugar. Researchers will give 80 healthy adults a drug that blocks a key hormone (GLP-1) and measure changes in glucose and insulin. The goal is to understand why this gene raises the risk of type 2 diabetes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE2DIABETES are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Mayo Clinic in Rochester
Rochester, Minnesota, 55905, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Exendin 9-39 (a drug that blocks GLP-1 receptors)
What this could lead to
If successful, this could help explain why some people are genetically prone to type 2 diabetes, potentially pointing toward new prevention strategies.
What could go wrong
This is a small, early-phase study focused on understanding biology, not testing a treatment. It may not lead to any direct medical benefit.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.